| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, Head Of R&D
1 company
Gallagher Neil is a President, Head Of R&D at SNDX. Recent filings cover 0 purchases and 1 sale. Those positions are worth an estimated $1.3M at current prices.
Gallagher Neil's largest disclosed position is in SNDX as President, Head Of R&D, worth about $1.3M. The recent filings there lean toward selling, a net 4,618 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2025 | SNDX Syndax Pharmaceuticals Inc | President, Head Of R&D | Sell | 4,618 | $15.50 | $71,597.47 | -5.1% | -27.4% | +40.9% |